LAFAYETTE, La., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will participate in the following upcoming investor conferences:
Baird Global Healthcare Conference - 2023
Casey Hoyt, CEO, will participate in a panel presentation to discuss home medical equipment & supplies market trends and outlook. Management will also host a formal 30 minute introductory investor presentation and host 1x1 meetings on Wednesday, September 13, 2023, in New York, NY.
Lake Street Capital Markets 7th Annual Best Ideas Growth Conference
Management will host 1x1 meetings on Thursday, September 14, 2023, in New York, NY.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen Akselrod
Bristol Capital
905-326-1888
This email address is being protected from spambots. You need JavaScript enabled to view it.
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.38 |
Daily Change: | -0.14 -2.15 |
Daily Volume: | 40,519 |
Market Cap: | US$248.440M |
March 10, 2025 November 06, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load